Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

IO Biotech Inc

Healthcare US IOBT

0.0065USD
0.0043(195.45%)

Last update at 2026-06-04T13:30:00Z

Day Range

0.00220.0075
LowHigh

52 Week Range

0.822.21
LowHigh

Fundamentals

  • Previous Close 0.0022
  • Market Cap84.99M
  • Volume868212
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-93.49425M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.7

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -70.18500M -67.81100M -12.04200M -10.74300M
Minority interest - - - -
Net income -71.45800M -67.87900M -12.06800M -10.74900M
Selling general administrative 24.44M 11.08M 1.68M 1.98M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation 0.54M - - -
Ebit -71.42400M -41.23400M -10.14500M -9.91300M
Ebitda -70.01300M -67.76900M -12.13000M -10.69400M
Depreciation and amortization 1.41M -26.53500M -1.98500M -0.78100M
Non operating income net other 1.54M - - -
Operating income -71.42400M -41.23400M -10.14500M -9.91300M
Other operating expenses 71.42M 41.23M 10.14M 9.91M
Interest expense 0.30M 0.36M 0.03M 0.00600M
Tax provision 1.27M 0.07M - -
Interest income 1.41M - - -
Net interest income 1.11M -0.36100M -0.02600M -0.00600M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 1.27M 0.07M 0.03M 0.00600M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 71.42M 41.23M 10.14M 9.91M
Cost of revenue - - - -
Total other income expense net 1.24M -26.57700M -1.89700M -0.83000M
Discontinued operations - - - -
Net income from continuing ops -71.45800M -67.87900M -12.04200M -10.74300M
Net income applicable to common shares -71.45800M -74.98700M -14.59400M -12.51700M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 150.72M 151.81M 222.29M 5.65M 9.42M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.94M 5.63M 10.21M 0.37M 0.10M
Total liab 17.56M 12.95M 10.36M 40.96M 32.95M
Total stockholder equity 133.16M 138.85M 211.92M -35.30300M -23.53100M
Deferred long term liab - - - - -
Other current liab 11.18M 6.16M 6.38M 2.53M 0.23M
Common stock 0.07M 0.03M 0.03M 0.03M 0.03M
Capital stock 0.07M 0.03M 0.03M 0.03M 0.03M
Retained earnings -263.82200M -177.73900M -106.28100M -38.40200M -26.36000M
Other liab - - 0.06M - 0.05M
Good will - - - - -
Other assets 0.00000M 0.35M 0.55M 0.02M 0.02M
Cash 143.19M 142.59M 211.53M 3.40M 7.85M
Cash and equivalents - - - - -
Total current liabilities 15.72M 10.68M 10.30M 3.05M 10.84M
Current deferred revenue - - - - 0.95M
Net debt -140.69900M -139.80000M -211.53100M -3.40500M 0.82M
Short term debt 0.66M 0.52M - - 8.66M
Short long term debt - - - - 8.66M
Short long term debt total 2.49M 2.79M - - 8.66M
Other stockholder equity 406.59M 326.70M 319.67M -36.79600M -20.55600M
Property plant equipment - 0.74M 0.15M - -
Total current assets 147.25M 148.22M 221.74M 5.63M 9.40M
Long term investments - - - - -
Net tangible assets - 138.85M 211.92M -35.30300M -23.53100M
Short term investments - - - - -
Net receivables 1.13M 1.53M 2.09M 1.50M 1.23M
Long term debt - - - - -
Inventory - -1.53300M -2.09100M 0.36M 0.22M
Accounts payable 3.88M 4.00M 3.93M 0.52M 1.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -9.66900M -10.14100M -1.48900M 1.96M 1.30M
Additional paid in capital - - - - -
Common stock total equity - 0.03M - - -
Preferred stock total equity - - - - -
Retained earnings total equity - -177.73900M - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.09M 0.35M 0.55M 0.02M 0.02M
Deferred long term asset charges - - - - -
Non current assets total 3.46M 3.59M 0.55M 0.02M 0.02M
Capital lease obligations 2.49M 2.79M - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.69000M -0.15300M - -
Change to liabilities -0.20300M 3.41M -0.47500M 0.10M
Total cashflows from investing activities -0.69000M -0.15300M -0.15300M -0.15300M
Net borrowings - - - 9.01M
Total cash from financing activities 0.00000M 252.95M 5.10M 9.01M
Change to operating activities 4.12M -4.18200M 0.62M 0.79M
Net income -71.45800M -67.87900M -12.04200M -10.74300M
Change in cash -68.94100M 208.39M -4.44100M -0.12500M
Begin period cash flow 211.80M 3.40M 7.85M 7.97M
End period cash flow 142.86M 211.80M 3.40M 7.85M
Total cash from operating activities -59.72900M -40.64600M -9.95600M -8.89100M
Issuance of capital stock 0.00000M 265.06M 5.12M 0.00000M
Depreciation 0.54M 0.00200M 0.00200M 0.00200M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock - - - -
Other cashflows from financing activities -0.69000M 137.84M 5.10M 9.01M
Change to netincome 6.86M 28.01M 1.94M 0.96M
Capital expenditures 0.69M 0.15M 0.15M 0.15M
Change receivables - - - -
Cash flows other operating 4.97M - - -
Exchange rate changes - - - -
Cash and cash equivalents changes -60.41900M - - -
Change in working capital 4.19M -0.77600M 0.15M 0.89M
Stock based compensation 7.04M 1.79M 0.06M 0.13M
Other non cash items -0.13000M 26.22M 1.87M 0.83M
Free cash flow -60.41900M -40.79900M -9.95600M -8.89100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
IOBT
IO Biotech Inc		 0.0043 195.45% 0.0065 - - - 0.77 0.46
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

IO Biotech Inc

Ole Maaløes Vej 3, Copenhagen, Denmark, 2200

Key Executives

Name Title Year Born
Dr. Mai-Britt Zocca Ph.D. Founder, Pres, CEO, Principal Financial Officer & Director 1967
Dr. Muhammad Al-Hajj Ph.D. Chief Scientific Officer 1971
Dr. Eva Ehrnrooth M.D., Ph.D. Chief Medical Officer 1964
Prof. Inge Marie Svane M.D., Ph.D. Founder & Clinical Advisor NA
Prof. Mads Hald Andersen Ph.D. Founder & Scientific Advisor NA
Anders Ljungqvist Founder NA
Prof. Per Thor Straten Founder NA
Ms. Amy B. Sullivan Chief Financial Officer NA
Mr. Brian Burkavage VP of Fin. & Chief Accounting Officer 1983
Mr. Mikkel Dybkjær VP of Corp. Fin. 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.